Market Overview

UPDATE: Piper Jaffray Downgrades IPC The Hospitalist on Valuation Ahead of Near-Term Fundamentals

Related IPCM
US Stock Futures Flat, Apple In Focus
IPC Hires New Senior Vice President of Sales And Marketing

In a report published on Tuesday, Piper Jaffray analyst Kevin K. Ellich downgraded IPC The Hospitalist (NASDAQ: IPCM) from Overweight to Neutral and maintained a price target of $50.

In the report, Piper Jaffray stated, "With the stock up ~35% YTD and at all-time highs, we think it is a good time to take profits as Q2 and Q3 are seasonally slower. While hospital admissions growth remains pressured, we believe Q2 is tracking in line with our expectations and company guidance for FY13 largely because management did a good job setting realistic expectations for the year. Despite our downgrade, we believe the long-term outlook for the acute and post- acute hospitalist industry remains attractive, even though the stock is ahead of near- term fundamentals."

IPC The Hospitalist closed on Monday at $53.38.

Latest Ratings for IPCM

DateFirmActionFromTo
Jul 2014Credit SuisseMaintainsNeutral
Jun 2014Credit SuisseMaintainsNeutral
Apr 2014Wells FargoUpgradesMarket PerformOutperform

View More Analyst Ratings for IPCM
View the Latest Analyst Ratings

Posted-In: Kevin K. Ellich Piper JaffrayAnalyst Color Downgrades Analyst Ratings

 

Related Articles (IPCM)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters